HYDROXYCHLOROQUINE MARKET ANALYSIS
Global Hydroxychloroquine Market : Key Developments
On May 2, 2023, Icannex Healthcare- medicinal cannabinoid and psychedelic therapy development company, started its Phase II trial of cannabidiol (CBD) and hydroxychloroquine combinational therapy in Rheumatoid Arthritis.
In November, 2020, Jubilant Pharma Limited- a manufacturer and supplier of radiopharmaceuticals and Aavis Pharmaceuticals Inc- a U.S based pharmaceutical company, announced the launch of Hydroxychloroquine tablets to counter Malaria , Rheumatoid Arthritis and Lupus in the U.S.
In April 2022, the Indian government lifted a ban on the export of hydroxychloroquine, paving the way for the anti-malaria drug to be shipped to the U.S. for use against the coronavirus.
In April 2020, Galenika- Serbia based pharmaceutical company and Zada Pharmaceuticals- a Bosnia based pharmaceutical company announced the launch of a production unit of chloroquine and hydroxychloroquine for the treatment of COVID-19 patients.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :